You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MACCE in Hospitalized Patients With Community-acquired Pneumonia

Recruiting
  • Community-acquired Pneumonia
    • Rome, Italy
      Internal and Medical Specialities Department - Policlinico Umber
    Sep 28, 2021

    Inclisiran on Major Adverse Cardiovascular Events in French

    Not yet recruiting
    • Atherosclerotic Cardiovascular Disease
    • Inclisiran sodium
    • +3 more
    • (no location specified)
    Jul 26, 2023

    Diabetes, Type 2, Major Adverse Cardiac Events Trial in Hangzhou (CGM)

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • Major Adverse Cardiac Events
    • CGM
    • Hangzhou, China
      the Second Affiliated Hospital Zhejiang University Schoolof Medi
    Sep 23, 2023

    Obesity Trial (Naltrexone-Bupropion (NB) Combination, Placebo)

    Not yet recruiting
    • Obesity
    • Naltrexone-Bupropion (NB) Combination
    • Placebo
    • (no location specified)
    Oct 18, 2023

    Major Adverse Cardiovascular Events in Coronary Artery Disease

    Completed
    • Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
      • Jinan, Shandong, China
        Yuguo Chen
      Sep 20, 2022

      Anticoagulant Drug Intervention on Postoperative MALE and MACE

      Recruiting
      • Anticoagulant Drugs
      • +2 more
      • anticoagulant or antiplatelet drugs
      • Hangzhou, None Selected, China
        First Affiliated Hospital of Zhejiang University
      May 8, 2023

      Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)

      Not yet recruiting
      • Arteriosclerosis
      • Hypercholesterolaemia
      • (no location specified)
      Aug 17, 2023

      Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke Trial (low-dose rivaroxaban, Standard-dose rivaroxaban)

      Not yet recruiting
      • Atrial Fibrillation
      • +3 more
      • low-dose rivaroxaban
      • Standard-dose rivaroxaban
      • (no location specified)
      Oct 25, 2023

      PASS to Assess Cardiovascular and Cerebrovascular Events in COPD

      Not yet recruiting
      • Chronic Obstructive Pulmonary Disease
      • Observational retrospective data collection
      • (no location specified)
      Dec 14, 2022

      Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)

      Not yet recruiting
      • Primary Prevention of Atherosclerotic Cardiovascular Disease
      • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
      • Placebo in 1.5ml
      • (no location specified)
      Feb 13, 2023

      Cardiovascular Primary Prevention Strategy Trial in Murray (Coronary Artery Calcium Screening and Statin Treatment, Standard

      Recruiting
      • Cardiovascular Primary Prevention Strategy
      • Coronary Artery Calcium Screening and Statin Treatment
      • Standard Treatment
      • Murray, Utah
        Intermountain Medical Center and Intermountain Clinics
      Aug 8, 2022

      Novel Cardiovascular Biomarkers in Patients With Kidney Disease

      Not yet recruiting
      • Haemodialysis Complication
      • Major Adverse Cardiac Events
      • Cardiac Biomarkers
      • +2 more
      • (no location specified)
      Sep 14, 2023

      MACCE According to Time Interval of Taking Medication in Acute

      Completed
      • Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
      • Esomezol Cap
      • Seoul, Korea, Republic of
        Hanmi Pharmaceutical Company Limited
      Aug 2, 2022

      Coronary Artery Disease Progression Trial (Intensive lipid-lowering control, Moderate-intensity lipid-lowering control)

      Not yet recruiting
      • Coronary Artery Disease Progression
      • Intensive lipid-lowering control
      • Moderate-intensity lipid-lowering control
      • (no location specified)
      Jul 13, 2022

      Coronary Artery Disease Trial in United States (Colchicine, Placebo)

      Not yet recruiting
      • Coronary Artery Disease
      • Long Beach, California
      • +4 more
      Nov 15, 2022

      Obstructive Hypertrophic Cardiomyopathy

      Completed
      • Microvascular Dysfunction
      • +2 more
        • Beijing, Beijing, China
          Fuwai Hospital, China National Center for Cardiovascular Disease
        Jan 11, 2023

        Cardiovascular Diseases Trial in Peking (cardiovascular magnetic resonance (CMR))

        Completed
        • Cardiovascular Diseases
        • cardiovascular magnetic resonance (CMR)
        • Peking, Beijing, China
          Chinese PLA General Hospital
        Apr 3, 2022

        CT-based Myocardial Characterization (CTMyoC)

        Recruiting
        • Different Cardiomyopathy and Major Cardiovascular Adverse Events
          • Milano, Italy
            IRCCS San Raffaele
          Sep 1, 2023

          Major Adverse Cardiovascular Events for Naldemedine and Other

          Recruiting
          • Opioid-induced Constipation
          • Wilmington, Delaware
            Research Site
          Feb 28, 2022

          GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Type 2

          Recruiting
          • Diabetes Mellitus, Type 2
          • Myocardial Infarction
          • PCI
          • Naples, Italy
            Celestino Sardu
          Aug 31, 2023

          High-Risk Percutaneous Coronary Intervention Trial (Impella ECP)

          Recruiting
          • High-Risk Percutaneous Coronary Intervention
          • Impella ECP
          • Detroit, Michigan
            Ascension St. John Hospital
          Dec 23, 2022

          Coronary Artery Disease Trial in Seoul (Clopidogrel treatment group, No antiplatelet or anticoagulant group)

          Recruiting
          • Coronary Artery Disease
          • Clopidogrel treatment group
          • No antiplatelet or anticoagulant group
          • Seoul, Other, Korea, Republic of
            Seoul National University Hospital
          May 9, 2023

          STEMI Trial (PPCI in heavy thrombus burden STEMI patients)

          Not yet recruiting
          • STEMI
          • PPCI in heavy thrombus burden STEMI patients
          • (no location specified)
          Mar 30, 2023

          Vascular Events In Patients Undergoing Same-day Noncardiac

          Recruiting
          • Preoperative Care
          • +2 more
            • Montreal, Quebec, Canada
            • +1 more
            Jul 28, 2022

            Impact of COVID-19 Vaccines on Cerebrovascular Health

            Recruiting
            • Stroke
            • +9 more
            • Laboratory tests and Montreal Cognitive Assessment
            • Hong Kong, Hong Kong
              Chinese University of Hong Kong
            Mar 7, 2022